25 studies found for:    HLA-DQA1
Show Display Options
Rank Status Study
1 Recruiting αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
Conditions: Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface;   Malignant Peritoneal Mesothelioma;   Peritoneal Carcinomatosis
Interventions: Biological: DC vaccine;   Drug: Celecoxib;   Drug: Interferon Alfa-2b;   Biological: rintatolimod
2 Completed HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease
Conditions: Celiac Disease;   Gluten
Intervention: Dietary Supplement: Gluten challenge.
3 Recruiting Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: androgen ablation + dendritic cell vaccine;   Biological: androgen ablation plus dendritic cell vaccine
4 Completed Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine 208129;   Biological: Engerix™-B
5 Completed Clinical Relevance of Typing HLA-DR7-DQ2
Conditions: Celiac Disease Patients Following Recommendations of ESPGHAN;   HLA-DQ2 Typing Include HLA-DR7-DQ2 Haplotypes
Intervention: Other: There is not any intervention
6 Completed Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome
Conditions: Diarrhea;   Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Other: Gluten free diet;   Other: Gluten rich diet
7 Recruiting DC Vaccine for Patients With Ductal Carcinoma In Situ
Conditions: Breast Cancer;   DCIS
Intervention: Biological: HER-2 Pulsed Dendritic cell Vaccine
8 Recruiting Pilot Phase I HER-2 Pulsed-DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy
Condition: Estrogen Independent Advanced Breast Cancer
Intervention: Biological: HER-2 pulsed DC1 vaccine
9 Recruiting Pilot Phase I HER-2 Pulsed DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer
Condition: Breast Cancer
Intervention: Biological: HER-2 pulsed DC1 vaccine
10 Recruiting HLA-DRB1 and HLA-DQB1 Genotyping for Autoantibody-positive and -Negative Patients With Atrophic Glossitis or Burning Mouth Syndrome
Condition: Atrophic Glossitis, Burning Mouth Syndrome
Intervention: Dietary Supplement: Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic
11 Unknown  Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast
Condition: Breast Cancer
Interventions: Biological: therapeutic autologous dendritic cells;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy
12 Active, not recruiting Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
Condition: Malignant Glioma
Interventions: Biological: Dendritic vaccine pulsed with multiple peptides;   Biological: The first booster vaccine phase:;   Biological: The second booster vaccine phase:
13 Recruiting Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: DC vaccine;   Drug: Dasatinib
14 Completed Safety Study of Nexvax2 in Subjects With Coeliac Disease
Conditions: Coeliac Disease;   Celiac Disease
Interventions: Biological: 9 micrograms Nexvax2;   Biological: 30 micrograms Nexvax2;   Biological: 90 micrograms Nexvax2;   Biological: 60 micrograms Nexvax2;   Biological: Up to 900 micrograms Nexvax2;   Other: Placebo
15 Completed The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.
Condition: Rheumatoid Arthritis
Intervention: Drug: Adalimumab
16 Terminated Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke
Condition: Ischemic Stroke
Intervention: Device: Nautilus NeuroWaveTM System
17 Recruiting HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy
Condition: Breast Cancer
Intervention: Biological: HER-2 pulsed Dendritic Cell Vaccine
18 Recruiting HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer
Condition: Breast Cancer
Intervention: Biological: HER-2 pulsed Dendritic Cell Vaccine
19 Active, not recruiting Bortezomib and Filgrastim in Promoting Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Stem Cell Transplant
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Small Lymphocytic Lymphoma;   Stage II Multiple Myeloma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: bortezomib;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation
20 Completed Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV
Condition: HIV Infections
Interventions: Drug: Abacavir sulfate, lamivudine, and zidovudine;   Drug: Lamivudine/zidovudine;   Drug: Lopinavir/ritonavir

Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results
Indicates status has not been verified in more than two years